GESTIÓN EN SALUD PÚBLICA: Mucosal IgA fused nanobody as a non-invasive, cost-effective prophylaxis and therapeutic option against major SARS-CoV-2 variants

sábado, 3 de diciembre de 2022

Mucosal IgA fused nanobody as a non-invasive, cost-effective prophylaxis and therapeutic option against major SARS-CoV-2 variants

Mucosal IgA fused nanobody as a non-invasive, cost-effective prophylaxis and therapeutic option against major SARS-CoV-2 variants

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)